Positron wins approval for radiopharmaceutical manufacturing facility in Indiana
Positron has received the approval of Nuclear Regulatory Commission (NRC) manufacturing and distribution license amendment for its radiopharmaceutical manufacturing facility in Crown Point, Indiana.
The company is currently producing Indium 111 Oxyquinoline for customer evaluation and commercial sale with plans to process additional radioisotopes for medical use.
Positron pharmaceuticals vice president Scott Stiffler said NRC approval completes the mandatory requirements qualifying its Crown Point site as a fully licensed and operational radiochemical manufacturing facility.
"The capabilities at the Crown Point facility will play a vital role in Positron's expansion into radiopharmaceutical and radiochemical production and further development of products relevant to our full solution strategy," Stiffler added.
CommentsPost a comment
Comments may be moderated for spam, obscenities or defamation.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs